Business Context and Reporting Period
This Form 8-K Current Report from Mangoceuticals, Inc. (MGRX) covers events occurring on March 17, 2025, specifically a Special Meeting of stockholders. The company is incorporated in Texas and trades on the Nasdaq Capital Market. The filing details the approval of amendments to the Series B Convertible Preferred Stock designation, changes to the 2022 Equity Incentive Plan, and the issuance of subsidiary securities to the CEO.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and capital structure modifications.
Material Changes and Corporate Actions
- Series B Preferred Stock Amendment: Stockholders approved a reduction in the conversion price of Series B Convertible Preferred Stock from $2.25 to $1.50 per share. The floor price was similarly reduced from $2.25 to $1.50. Dividend rights were removed, retaining only standard participatory rights.
- Change of Control Definition: The amendment excludes the company's wholly-owned subsidiary, Mango & Peaches Corp., from the definition of a "Change of Control Transaction." This prevents the issuance of securities to CEO Jacob Cohen from triggering a default or equity condition under the Series B terms.
- Equity Incentive Plan: Stockholders approved the Second Amendment to the 2022 Equity Incentive Plan. The plan allows for an aggregate of 10,000,000 shares initially, with an "evergreen" provision allowing annual increases of the lesser of 10% of outstanding shares or 2,000,000 shares, capped at a total of 26,000,000 shares.
- CEO Issuance: Stockholders approved the issuance of common stock and Series A Super Majority Voting Preferred Stock of Mango & Peaches Corp. to CEO Jacob Cohen pursuant to Nasdaq Listing Rule 5635.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance, management commentary on operational outlook, or specific risk factors beyond the structural changes to the capitalization. The primary contingency addressed is the modification of the Series B Preferred Stock terms to facilitate the issuance of subsidiary equity to the CEO without triggering default provisions.
Investor Verification Checklist
- Verify the impact of the reduced $1.50 conversion price on potential common stock dilution (up to 1,872,994 shares from 2,554 Series B shares).
- Review the full text of the Second Amendment to the 2022 Equity Incentive Plan (Exhibit 10.2) to understand specific vesting and grant terms.
- Confirm the details of the securities issued to CEO Jacob Cohen in Mango & Peaches Corp. as referenced in Proposal 3.
- Monitor the "evergreen" provision of the equity plan, which could increase the share pool annually starting April 1, 2026.